Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage
1. In this retrospective cohort study, the incidence of hydroxychloroquine retinopathy was 2.5% at 10 years, increasing to 8.6% at...
1. In this retrospective cohort study, the incidence of hydroxychloroquine retinopathy was 2.5% at 10 years, increasing to 8.6% at...
1. At week 16, all rocatinlimab groups reported significant improvements in eczema severity. 2. Most treatment-related adverse events were mild-to-moderate,...
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections...
1. In this retrospective, cohort, control-matched study, a diagnosis of juvenile idiopathic diabetes was associated with an increased risk of...
1. Among patients with primary Sjögren syndrome, therapy with low-dose interleukin 2 significantly improved outcomes as determined by the European...
1. Self-administered subcutaneous immunoglobulin therapy in the treatment of immunodeficiencies is significantly less costly compared to clinic-administered intravenous immunoglobulin therapy....
1. The composite score for non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death was comparable between allopurinol (11.0%) and usual...
1. Compared to a control group, patients with knee osteoarthritis who engaged in online yoga had improvements in pain and...
1. An increased incidence of new cardiovascular disease was seen in individuals with autoimmune disease compared to those without. 2....
1. Litifilimab was associated with a reduction in the number of swollen and tender joints in systemic lupus erythematosus (SLE)...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.